Monopar Therapeutics (MNPR) earlier today announced that the Journal of Hepatology published a peer-reviewed letter to the editor, authored by Wilson disease physicians, entitled “Oral Bis-choline Tetrathiomolybdate Rapidly Improves Copper Balance in Patients with Wilson Disease.” In the letter, the authors explain that the earlier conclusion from the Phase 2 ALXN1840-WD-204 study – that ALXN1840 did not promote copper excretion – was based on a methodological limitation in the copper balance equation, which only accounted for certain routes of copper loss, the company noted. By controlling for the other routes of copper loss by comparing pre- and post-ALXN1840 treatment, the analysis demonstrates that ALXN1840 statistically significantly improved copper balance over the duration of the study, according to Monopar. Shares of Monopar are up 6% to $4.14 to $71.82 in morning trading.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- CoreWeave upgraded, Lululemon downgraded: Wall Street’s top analyst calls
- Monopar Therapeutics initiated with a Buy at Lake Street
- Monopar Therapeutics management to meet virtually with Piper Sandler
- Promising Long-Term Efficacy and Safety of ALXN1840 Strengthens Buy Rating for Monopar Therapeutics Inc.
- Monopar Therapeutics Presents New Data on ALXN1840